论文部分内容阅读
目的：评价拉莫三嗪辅助治疗血管性认知障碍的临床疗效及安全性。方法将98例血管性认知障碍患者随机分为试验组49例和对照组49例。试验组口服拉莫三嗪起始剂量为50 mg· d－1，4周内剂量加至100～200 mg· d－1；对照组口服碳酸锂，起始剂量为500 mg · d－1，4周内剂量加至1000～2000 mg· d－1。2组患者均治疗8周。观察2组患者的临床疗效、倍克－拉范森躁狂量表（ BRMS）与临床总体疗效－疾病严重程度（ CGI－SI ）评分变化情况、P300与N400潜伏期变化情况与不良反应发生率。结果试验组的有效率（95.92％）明显高于对照组（81.63％）（ P＜0.05）。与治疗前比较，2组治疗后的BRMS与CGI－SI评分都呈现明显下降的趋势（ P＜0.05），且试验组治疗后的BRMS与CGI－SI评分明显低于对照组（ P＜0.05）。与治疗前比较，2组治疗后的P300与N400潜伏期都明显缩短，而波幅明显增加（P＜0.05），且试验组治疗后的P300与N400潜伏期、波幅与对照组比较差异均有统计学意义（ P＜0.05）。试验组出现皮疹2例、头晕1例和恶心1例；对照组出现眩晕1例、恶心1例、嗜睡1例，减药后不良反应减轻或消失，差异无统计学意义（ P＞0.05）。结论拉莫三嗪辅助治疗血管性认知障碍能有效地缓解病情与躁狂症状，改善事件相关电位，从而促进临床总体疗效的提高，且安全性好。“,”Objective To investigate the clinical efficacy and safety of lamotrigine adjunctive therapy for vascular cognitive impairment.Methods Ninety -eight vascular cognitive impairment patients were divided into treatment group and control group, each group was 49 patients.In treatment group, every patients were received lamotrigine 50 mg· d-1 in the start dose, and increased to 100-200 mg· d-1 within four weeks.In control group, every patient was received lithium carbonate 500 mg· d-1 in the start dose, and increased to 1000-2000 mg· d-1 within four weeks.All patients were given eight weeks of treatment.Observed the efficacy, Bech -Rafaelsen mania rating scale (BRMS) and clinical global impression-severity of illness (CGI-SI) score changes, P300 and N400 latency changes and adverse reactions.Results The response rates in the treatment group and the control group were 95.92% and 81.63% respectively that the treatment group had significantly higher efficiency ( P<0.05 ).After treatment, the BRMSand CGI-SI scores were showing clear downward trend with a significant difference compared pre-treatment in the two groups( P<0.05 ) , and the the BRMS and CGI-SI scores in the treatment group were significantly lower than the control group after treatment ( P <0.05 ).After treatment, the P300 and N400 latencies were significantly shorter, while the volatility were increased significantly, with were significant differences compared pre-treatment ( P<0.05 ) , while the P300 and N400 latency and amplitude in the treatment group compared with the control group were statistical difference significance ( P<0.05 ).During the treatment, there were two patients were rash, one patient was dizziness and one patient was nausea in the treatment group; there were one patient was dizziness, one patient was nausea, one patient was lethargy.Conclusion Lamotrigine adjunctive therapy vascular cognitive impairment can effectively alleviate the condition and manic conditions, improve time-related potentials, thereby it is contributing to improve the overall clinical efficacy and safety.